KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Progyny (PGNY) Cash & Equivalents (2018 - 2025)

Progyny (PGNY) has disclosed Cash & Equivalents for 8 consecutive years, with $112.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents changed N/A to $112.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $112.2 million, a N/A change, with the full-year FY2025 number at $112.2 million, changed N/A from a year prior.
  • Cash & Equivalents was $112.2 million for Q4 2025 at Progyny, down from $134.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $170.6 million in Q2 2023 to a low of $29.8 million in Q1 2021.
  • A 5-year average of $101.0 million and a median of $97.3 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: crashed 67.46% in 2021, then soared 300.09% in 2023.
  • Progyny's Cash & Equivalents stood at $91.4 million in 2021, then surged by 31.36% to $120.1 million in 2022, then decreased by 18.97% to $97.3 million in 2023, then dropped by 5.98% to $91.5 million in 2024, then increased by 22.69% to $112.2 million in 2025.
  • Per Business Quant, the three most recent readings for PGNY's Cash & Equivalents are $112.2 million (Q4 2025), $134.0 million (Q3 2025), and $132.5 million (Q2 2025).